SPEAKING THE LANGUAGE OF PROTEINS
Artificial Intelligence approaches have the potential to improve drug discovery along all the three axes: to make it faster; optimize the cost; and make the drugs more quality and effective to increase the success rate.
Our Product
The core product is a modular software platform with AI solutions for therapeutic antibody design and optimization tasks that arise in the lead generation and lead optimization stages of an antibody development project.
OUR MODULES
GENERATION OF ANTIBODY CANDIDATES
Giving as an imput the amino acid sequence of the target or the epitope residues, our "Generator" module delivers in return antibody candidates represented as amino acid sequences of heavy and light antibody chains corresponding to the antibody variable fragment (Fv).
VIRTUAL SCREENING AND SELECTION OF CANDIDATES
Our Discriminator module predicts with high accuracy the probability of being a binder against the specified epitope, developability index, thermal stability index, solubility index, self-aggregation index, and immunogenicity index.
OPTIMIZATION OF CANDIDATES
Our "Optimizer" module adapts the candidates to fulfill a program-specific target product profile (TPP), giving as result mutated amino acid sequences of candidates with predicted characteristics from the TPP.
THE BENEFITS
Create an alliance with Silica Corpora and benefit from the inconmensurable capabilities of Artificial Intelligence in Drug Discovery
SHORTEN STEPS AND MAKE THE PROCESS MORE AGILE:
The discovery process and preclinical stages could be accelerated by a factor of 15 by the successful implementation of AI algorithms by understanding the protein-drug interaction and structure prediction based on AI analysis or identifying new targets from AI analysis of phenotypic results.
EXPAND AND INCREASE DRUG PIPELINES
Accelerate and enhance preclinical testing and discovery, enabling new research ventures and more competitive R&D tactics. The ability to find new bio-betters compared to existing treatments is a key factor for the success of established companies, as well as finding new niches of operation.
DESIGN, NOT DISCOVERY
The understanding of the mechanisms of action of targets and how medications can bind them are both being transformed by Artificial Intelligence. Our platform allows companies and research centres to design from scratch their desired Antibodies instead of discovering them.